Olaparib monotherapy versus chemotherapy for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: Asian subgroup analysis from the phase III OlympiAD trial Meeting Abstract


Authors: Im, S. A.; Xu, B.; Li, W.; Robson, M.; Ouyang, Q.; Yeh, D. C.; Iwata, H.; Park, Y. H.; Sohn, J. H.; Tseng, L. M.; Goessl, C.; Wu, W.; Runswick, S.; Masuda, N.
Abstract Title: Olaparib monotherapy versus chemotherapy for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: Asian subgroup analysis from the phase III OlympiAD trial
Meeting Title: 40th Annual San Antonio Breast Cancer Symposium (SABCS 2017)
Journal Title: Cancer Research
Volume: 78
Issue: 4 Suppl.
Meeting Dates: 2017 Dec 5-9
Meeting Location: San Antonio, TX
ISSN: 0008-5472
Publisher: American Association for Cancer Research  
Date Published: 2018-02-01
Language: English
ACCESSION: WOS:000425489402047
PROVIDER: wos
DOI: 10.1158/1538-7445.SABCS17-P5-21-13
Notes: Meeting Abstract: P5-21-13 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Mark E Robson
    677 Robson